Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Bradmer Pharmaceuticals Inc. (T.GLX) had Normalized Income after Taxes of -0.24M for the most recently reported fiscal year, ending 2017-12-31.
| Income Statement Financials | |
-- |
|
-0.24M |
|
-- |
|
-- |
|
-- |
|
-0.21M |
|
-- |
|
-0.24M |
|
-0.24M |
|
-0.24M |
|
-0.24M |
|
-0.24M |
|
|
Normalized Income after Taxes |
-0.24M |
-0.21M |
|
-0.21M |
|
0.16M |
|
0.16M |
|
-1.48 |
|
-1.48 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
0.42M |
|
-- |
|
-- |
|
-- |
|
0.14M |
|
0.28M |
|
0.28M |
|
0.28M |
|
0.16M |
|
| Cash Flow Statement Financials | |
-0.16M |
|
-- |
|
-- |
|
0.54M |
|
0.41M |
|
-0.12M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-0.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-84.62% |
|
-84.62% |
|
-57.12% |
|
-84.62% |
|
1.82 |
|
-1.01 |
|
-1.01 |
|